Joyce Fu Liu MD

Oncology•Charlestown, MA

Instructor in Medicine, Dana-Farber Cancer Institute

Join to View Full Profile

55 Fruit Street Yawkey 7604Mass General Physician OrganizationCharlestown, MA 02129
Phone+1 617-726-2782
Fax+1 617-726-2894

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2008
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
Harvard Medical SchoolClass of 2002

Certifications & Licensure

FL State Medical License 2022 - Present
VT State Medical License 2023 - 2026
MA State Medical License 2004 - 2025
NH State Medical License 2024 - 2024
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Apr 14
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer Start of enrollment: 2011 Apr 01
Completed
Phase 2
A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
Completed
Phase 1
AO-176 in Multiple Solid Tumor Malignancies Start of enrollment: 2019 Feb 04
Completed
Phase 1, Phase 2
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Start of enrollment: 2018 Oct 22
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2018 Dec 07
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Principal Investigator
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib Start of enrollment: 2016 Nov 10
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors Start of enrollment: 2021 Feb 25
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Start of enrollment: 2023 Sep 14
RECRUITING
PHASE1
Roles: Principal Investigator, Contact
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Start of enrollment: 2023 Nov 14
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Azenosertib in Uterine Serous Carcinoma: Biomarker Study Start of enrollment: 2025 Apr 01
RECRUITING
PHASE2
Roles: Sponsor-Investigator, Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

DirectHRD enables sensitive scar-based classification of homologous recombination deficiency.
Ruolin Liu, Eugenia Roberts, Heather A Parsons, Elizabeth H Stover, Atish D Choudhury
Nucleic Acids Research. 2025-04-22
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uter...
Joyce F Liu, Nicoletta Colombo, Amit M Oza, Jean-Sebastien Frenel, Bradley R Corr
Journal of Clinical Oncology. 2025-04-22
Shedding LIGHT on the changing landscape of poly-ADP ribose polymerase inhibitors in ovarian cancer.
Melissa K Frey, Joyce F Liu
Cancer. 2025-04-15

Lectures

A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Nivolumab/bevacizumab Combo Promising in Relapsed Ovarian CancerOctober 19th, 2019
OncLive® Presents Latest State of the Science Summit™ on Ovarian Cancer and STSNovember 29th, 2018
Update Sustains Olaparib/Cediranib PFS Benefit in Ovarian CancerJune 9th, 2017
Join now to see all